Rapid Communication
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Apr 28, 2008; 14(16): 2561-2565
Published online Apr 28, 2008. doi: 10.3748/wjg.14.2561
Table 1 Demographic and clinical data of the study patients (n = 100)
ParameterNo erythromycinErythromycinP
(n = 50)(n = 50)
Age, yr (mean ± SD)51.7 ± 21.652.1 ± 19.40.931
Male/Female32/1836/140.39
Indications0.40
Suspected Crohn’s19180.84
Obscure GI bleeding23280.32
Others2840.22
Final diagnosis in SB0.10
Normal findings23190.42
Non-specific findings970.59
Crohn’s disease170.06
Angiodysplasia720.16
Polyps130.62
Others29120.46
Table 2 Transit times, bile and cleanliness scores in the two study groups (mean ± SD)
No erythromycinErythromycinP
(n = 50)(n = 50)
Gastric transit time (min)28.36 ± 23.5621.08 ± 15.130.071
0.16
SB transit time (min)270.42 ± 108.13279.14 ± 103.890.83
Total transit time (min)299.26 ± 108.18300.22 ± 103.250.97
Did not reach the cecum (%)8 (16%)5 (10%)0.37
Bile presence score1.75 ± 0.611.76 ± 0.580.99
Cleanliness score
Proximal SB1.78 ± 0.761.77 ± 0.741.00
Middle SB2.22 ± 0.752.16 ± 0.770.73
Distal SB2.79 ± 0.652.75 ± 0.740.73
Table 3 Gastric transit time with respect to cecum reachability
No erythromycinErythromycinP
(n = 50)(n = 50)value
Gastric transit time in cases failing to reach cecum (min)36.75 ± 33.93 (n = 8)22.2 ± 14.45 (n = 5)0.52
Gastric transit time in cases where cecum was reached (min)26.76 ± 21.22 (n = 42)20.96 ± 15.36 (n = 45)0.24
P0.520.81
Table 4 Transit times according to indication for capsule endoscopy in Crohn’s disease and obscure gastrointestinal bleeding (OGIB)
Transit timeIndicationNo erythromycinErythromycinP
(n = 50)(n = 50)
Gastric transit time (min)Crohn’s disease27.16 ± 26.1116.72 ± 13.210.19
OGIB29.82 ± 23.5323.61 ± 16.490.43
P0.410.16
Small bowel transit time (min)Crohn's disease285.53 ± 96.31324.50 ± 114.570.28
OGIB230.39 ± 103.00255.32 ± 90.810.44
P0.0660.04